Speciality Medicines
- Market cap
- ₹ 124 Cr.
- P/E
- 9.2x
- P/B
- 1.84x
- 52-week range
- 121.1 – 381.2
- ROE
- 26%
- ROCE
- 25%
- Debt / equity
- 0.09
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Speciality Medicines Limited is an India-based pharmaceutical company. The Company is engaged in marketing and distribution of finished formulations of specialty pharmaceuticals. It offers a diverse portfolio of specialty pharmaceuticals, focusing on therapeutic areas such as oncology, immunology, neurology, and rare diseases. It deals in finished formulations of specialty pharmaceuticals, including capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nasal spray, ointment, ophthalmic, oral solution, oral suspension, sachet, suspension and tablet. Its product portfolio consists of more than 900 products, which comprises of wide range of therapeutic drugs such as ACE inhibitors, Analgesic, Antiulcer, Anti angiogenic, Anti-acne, and Anti fibrinolytic, among others. Under the sale of specialty pharmaceutical finished formulation in the domestic market, it sources existing Indian medicine brands from manufacturers and their authorized distributors.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Speciality Medicines against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)9.2 against a typical 34.3: cheaper than most peers (1st = cheapest).16th of 220
- Share price, 3 months−27.3% against a typical −0.5%.192nd of 200
- Size₹ 123.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).141st of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 4 | 8 |
| Tax % | 36% | −1% |
| Net Profit | 3 | 8 |
| EPS in Rs | 4.16 | 9.31 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 48%
- TTM
- 29%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 98%
- TTM
- 81%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 29%
- 3 Years
- 27%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Speciality Medicines | ₹ 136.00 | ₹ 124 Cr. | 9.2x | 1.8x | 26% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 34.6x | 5x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 91.9x | 14.4x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 69.6x | 18.4x | — | 13.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,08,738 Cr. | 125.1x | 21.1x | — | 15% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.6x | 4.1x | — | 15.7% |
Management
- Parthkumar Babulal Goyani
- Executive Chairman of the Board, Managing Director
- Kalpesh Bharatbhai Pipaliya
- Chief Financial Officer
- Anita Kumawat
- Compliance Officer, Company Secretary
- Sumit Babubhai Goyani
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.